This rapidly growing Genetic Monitoring Facility is used by 20 peer-reviewed, funded investigators from 8 Research Programs using animal models in 36 research protocols. In 2003, 97.7% of the research projects utilizing this Facility were supported by peer-reviewed funding. Good genetic monitoring has become critical to the laboratory animal needs of the Fox Chase Cancer Center (FCCC) research community, as animals used in today's biomedical research must not only be free of disease, but also be well defined in terms of their genetic makeup. At present, we monitor 11 different loci located on 9 different chromosomes. We are currently maintaining 170 lines of mice for FCCC investigators and continue to add an average of one new transgenic line per month. During the past year, the Facility has performed 5,856 genetic profile tests, a 225% increase from the 1,800 performed in 1999. Service hours for genetic monitoring services have also increased dramatically, up 140% from 342 in 1999 to 821 in 2003. The daily operation of breed ng colonies is handled by personnel trained and experienced in genetic management and record-keeping. Regular review, advice and guidance is provided by Bruce Elder, Ph.D., a consultant geneticist added in March 2004 who makes quarterly visits and reviews reports and activities in all rodent colonies, and all of the breeding, production and genetic monitoring records have been computerized. These computerized records enable us to closely monitor breeding performance, pedigree lines, and utilization of the various inbred lines and strains. The ability to monitor the genome, and maintain the breeding colonies, of unique immunodeficient and transgenic mice enhances the interaction among Members of the Immunobiology Program as well as Members of the Cellular and Developmental Biology (Burch), Mintz (Tumor Cell Biology), Human Genetics (Testa, Program Leader), Developmental Therapeutics (Kruh, Smith, Weiner, Program Leader), and Cancer Prevention and Control (Clapper) Programs. Genetic Monitoring services have become a critical part of research with animals, and the need for services is expected to continue to increase 18% per year in the future. We propose adding one FTE to support this increase in Facility activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-45
Application #
7467240
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
45
Fiscal Year
2007
Total Cost
$172,338
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952

Showing the most recent 10 out of 1280 publications